George Miller - West Pharmaceutical President
| WST Stock | USD 336.34 0.86 0.26% |
President
Mr. George Lloyd Miller, J.D., is Senior Vice President, General Counsel, Corporationrationrate Secretary of West Pharmaceutical Services, Inc. He is Senior Vice President, General Counsel and Corporationrationrate Secretary since joining West in November 2015. Previously, he served as Senior Vice President, General Counsel and Corporationrationrate Secretary for SigmaAldrich Corporation from 2009 to 2015. Prior to working at SigmaAldrich, he held senior legal positions with Novartis AG, a global healthcare company. since 2015.
| Age | 64 |
| Tenure | 10 years |
| Address | 530 Herman O. West Drive, Exton, PA, United States, 19341-1147 |
| Phone | 610 594 2900 |
| Web | https://www.westpharma.com |
West Pharmaceutical Management Efficiency
The company has Return on Asset of 0.1 % which means that on every $100 spent on assets, it made $0.1 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1778 %, implying that it generated $0.1778 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, West Pharmaceutical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.15 in 2025, whereas Return On Capital Employed is likely to drop 0.10 in 2025. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4.6 B in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 307.8 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Brian Andrews | The Cooper Companies, | 46 | |
| Alexandre Conroy | Becton Dickinson and | 57 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Christopher Reidy | Becton Dickinson and | 64 | |
| Simon Campion | Becton Dickinson and | 49 | |
| John Deren | Teleflex Incorporated | N/A | |
| Sean Martin | Baxter International | 58 | |
| Alberto Mas | Becton Dickinson and | 59 | |
| William Burke | Haemonetics | 52 | |
| Christopher DelOrefice | Becton Dickinson and | 53 | |
| Lisa Kudlacz | Teleflex Incorporated | N/A | |
| Praneet Mehrotra | Teleflex Incorporated | N/A | |
| Richard McHale | ResMed Inc | 54 | |
| Cameron Hicks | Teleflex Incorporated | 60 | |
| Daniel McBride | The Cooper Companies, | 56 | |
| David Hickey | Becton Dickinson and | 60 | |
| Virginia Sanzone | ICU Medical | 50 | |
| Andrew Frye | Baxter International | 59 | |
| Thomas Spoerel | Becton Dickinson and | 46 | |
| Jennifer Schneiders | Hologic | 56 | |
| Michelle Basil | Haemonetics | 52 | |
Management Performance
West Pharmaceutical Leadership Team
Elected by the shareholders, the West Pharmaceutical's board of directors comprises two types of representatives: West Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of West. The board's role is to monitor West Pharmaceutical's management team and ensure that shareholders' interests are well served. West Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, West Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Buthman, Independent Director | ||
| Deborah Tanner, Independent Director | ||
| Bernard Birkett, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Eric Green, President, Chief Executive Officer, Director | ||
| John CFA, Head Relations | ||
| Rudy Poussot, Senior Development | ||
| Kathy DePadua, Senior Officer | ||
| Dr CFA, Vice Relations | ||
| William Feehery, Independent Director | ||
| Aileen RuffPatry, President Manufacturing | ||
| Robert Friel, Independent Director | ||
| Richard Luzzi, VP HR | ||
| Myla LaiGoldman, Independent Director | ||
| Paula Johnson, Independent Director | ||
| Douglas Michels, Independent Director | ||
| Michele Polinsky, Vice Communications | ||
| Kimberly MacKay, Senior Vice President General Counsel, Corporate Secretary | ||
| Don OCallaghan, President Devices | ||
| Paolo Pucci, Independent Director | ||
| Annette Favorite, Chief Human Resource Officer, Senior Vice President | ||
| Patrick Zenner, Independent Chairman of the Board | ||
| Thomas Hofmann, Independent Director | ||
| Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer | ||
| David Montecalvo, Senior Vice President, Chief Operating and Supply Chain Officer | ||
| Christopher Ryan, Senior Vice President of Commercial Products and Emerging Markets | ||
| Quintin Lai, Vice President - Corporate Development, Strategy and Investor Relations | ||
| Molly Joseph, Director | ||
| Andy Polywacz, President Systems | ||
| George Miller, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles CPA, VP Treasurer | ||
| Cindy ReissClark, Senior Vice President of Global Market Units and Commercial Solutions | ||
| Chad Winters, Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Robert Segura, VP Devel | ||
| Eric Resnick, Chief Technology Officer, Vice President |
West Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is West Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 24.17 B | ||||
| Shares Outstanding | 72.42 M | ||||
| Shares Owned By Insiders | 0.58 % | ||||
| Shares Owned By Institutions | 96.88 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| Price To Earning | 40.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.